Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

Gerald tweeted on Thursday that he would update the market on LymPro "soon". It's interesting to note that he did this after the market discounted the news of a third orphan indication for MANF.

It's obvious that the market is tiring of the continued tremendous dilution. If the LymPro update doesn't contain some indication of the potential for near term revenue I fully expect the share price will retrace to the .05 range or lower.

There's still 85,000,000 shares at .04 from the eventual conversion of the debentures that creates a substantial roadblock to a higher price.

Gerald is running out of shares much faster than most shareholders thought would be the case.

I'm not suggesting that anyone sell. I am suggesting that there may be a much better price over the next 2-3 weeks for anyone wanting to average down.

Just saying!!!